ClinicalTrials.gg
RecruitingNCT06919003IMPROVEUpdated Feb 27, 2026

Improving Deceased-Donor Kidney Transplant Outcomes Via a Single Intragraft Injection of C1 Esterase Inhibitor (IMPROVE TRIAL)

A Phase 2 interventional study of Berinert and Placebo for Berinert in Kidney Transplant, sponsored by National Institute of Allergy and Infectious Diseases (NIAID). Recruiting at 4 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-02-27.

Sponsored by National Institute of Allergy and Infectious Diseases (NIAID) · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2025; still recruiting 1 year 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
180
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies testing C1 esterase inhibitor (human) in Angioedemas, Hereditary — 1 open to participants now, 1 under way, none of them phase 3. C1 esterase inhibitor (human) · Angioedemas, Hereditary.

Planned enrollment
Largest of 11
180 · median 32
Started
2025
the only one that year
Phase 2
8 of 11
1 open now
Registered
11th of 11
by date
Lead sponsor
1 of 11
National Institute of Allergy and Infectious Diseases (NIAID)

Among the 11 studies testing C1 esterase inhibitor (human) in Angioedemas, Hereditary, this one has the largest planned enrollment, is the only one that started in 2025, is one of 8 in phase 2, and was the 11th registered.

Angioedemas, Hereditary

171 studies on the registry are indexed under Angioedemas, Hereditary; 24 are open to participants now.

Browse Angioedemas, Hereditary studies →

Open to participants now

1 of the 11 studies testing C1 esterase inhibitor (human) in Angioedemas, Hereditary is open now, in 1 country.

By country, each count listing its studies:

About C1 esterase inhibitor (human)

C1 esterase inhibitor (human): first FDA approval 2008 (Cinryze), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 13 Angioedemas, Hereditary studies recruiting now, 9 (69%) set no upper age limit and 4 (31%) stop at 75 or younger; 7 take children under 18; 1 takes healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies testing C1 esterase inhibitor (human) in Angioedemas, Hereditary, or all of them as a file.
02

Study summary

The purpose of this study is to find out if Berinert can improve kidney function in the first year after transplant and to find out what effects, good or bad, Berinert will have in the kidney recipient. This research study will compare Berinert to placebo. The placebo looks exactly like Berinert but does not contain any active drug. Placebos are used in research studies to see if the results are due to the study drug or due to other reasons. Neither you or the study doctor can choose or know which group is assigned.

The primary objective is to test whether intrarenal artery C1 esterase inhibitor (C1INH) injection into the donor kidney prior to transplantation improves kidney function in recipients of high risk, deceased donor kidney transplants as measured by 12-month Estimated Glomerular Filtration Rate (eGFR) Chronic Kidney Disease Epidemiology Collaboration (CDK-EPI)

03

Conditions studied

  • Kidney Transplant

Keywords

  • Kidney transplant
  • Deceased donor
  • Intragraft injection
  • C1 esterase inhibitor
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participant must be able to understand and provide
  2. Adults who are on chronic dialysis therapy and are on the wait list for deceased donor kidney transplant
  3. Recipients who are ABO compatible with donor allograft
  4. Negative crossmatch and no donor specific anti-HLA antibody (DSA) on most recent pretransplant serum sample as determined by local site
  5. Female participants of must have a negative pregnancy test upon study entry
  6. All participants with must agree to use highly effective for at least 12-moths post-transplant. Oral estrogen containing contraception must not be used during the first 3 months post-transplant
  7. Virus Ab positive participants with negative Hepatitis C virus (HCV) Polymerase chain reaction (PCR) are eligible if they have spontaneously cleared infection or are in sustained virologic remission
  8. Hepatitis C Virus negative recipients of a Hepatitis C Virus positive organ are eligible if they will be treated with the intent of inducing a sustained virologic remission
  9. Recipients of kidneys arriving to the transplant center on ex vivo hypothermic machine perfusion pumps are eligible
  10. Recipients of kidneys that received in situ normothermic regional perfusion in the donor are eligible. Kidneys that received normothermic machine perfusion after organ procurement (ex situ normothermic perfusion) are not eligible (See Exclusion #4)
  11. Anticipated Cold Ischemia Time (CIT) >=12 hours
  12. Kidney Donor Profile Index (KDPI) 21-95%. For KDPI 21-34% to be eligible, anticipated CIT must be >=24 hours
  13. Patients with normal coagulation

Exclusion criteria

Exclusion Criteria:

  1. Inability or unwillingness of a participant to give written or comply with study protocol
  2. Any prior or concurrent non-renal solid organ, or cellular transplant, or waitlisted for multi-organ transplant. Prior transplant is allowed
  3. Patients receiving enbloc kidneys
  4. Kidneys that received ex vivo normothermic machine perfusion after procurement. Kidneys that received in situ normotherimic regional perfusion in the donor are eligible (see Inclusion #10)
  5. Patients with a known pro-thrombotic disorder
  6. Patients with a history of thrombosis or hyper-coagulable state, excluding dialysis access clotting or other superficial vein thrombosis not requiring long-term systemic treatment
  7. (BMI) >=40 kg/m\^2
  8. Patients with a history of Hereditary Angioedema or use of C1 esterase inhibitor (C1INH) containing products or recombinant C1INH within 15 days prior to study entry
  9. Patients with a known to treatment with Berinert
  10. Patients requiring chronic anti-coagulation or anti- therapy. ASA and NSAIDS are allowed
  11. Presence of active or history of malignancy less than 5 years in remission, excluding adequately treated in-situ cervical carcinoma, low grade prostate carcinoma, renal cell carcinoma stage T1N0M0 that has been treated with nephrectomy, or adequately treated basal or squamous cell carcinoma of the skin
  12. Patients who are positive for Hep B infection ( surface antigen (HBsAg)+); patients with HbcAB+ are eligible if HBV PCR is negative
  13. Any active infection
  14. (HIV) infection
  15. Enrollment in another trial
  16. Recent recipient of any licensed or investigational (s) within 4 weeks of enrollment
  17. Current or planned use of immunomodulatory agents including but not limited to rituximab, belatacept, eculizumab, JAK inhibitors, anti-TNF agents
  18. Female participants who are pregnant or lactating
  19. Past or current medical problems, inclusive of mental health and substance abuse concerns, or findings from physical examination or laboratory testing that are not listed above, which, in the opinion of the investigator, may pose additional risks from participation in the study, may interfere with the participant's ability to comply with study requirements or that may impact the quality or interpretation of the data obtained from the study
  20. History of any stroke (including ischemic, hemorrhagic, or embolic) within the previous 6 months
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
180 participants (estimated)

Study arms

  • Experimental
    Berinert

    Biological: Berinert

  • Placebo comparator
    Saline

    Other: Placebo for Berinert

Interventions

  • BiologicalC1 esterase inhibitor (human)Studies of C1 esterase inhibitor (human)C1 esterase inhibitor (human) pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Administered as a 10 ml renal artery infusion approximately 1-2 hours before implantation and reperfusion of the allograft

    Also known as: C1 esterase inhibitor, C1INH

  • OtherPlacebo for Berinert

    Administered as a 10 ml renal artery infusion approximately 1-2 hours before implantation and reperfusion of the allograft

06

What researchers measure

Primary outcomes

  1. Difference between study arms in renal function

    Measured as Estimated Glomerular Filtration Rate Chronic Kidney Disease Epidemiology Collaboration (eGFRCKD-EPI) in ml/min/1.73m\^2

    Time frame: At 12-months post-transplantation

Secondary outcomes

  1. Comparison between the treated and control group of the full iBox score

    The iBox scoring system is a composite biomarker panel. The full iBox scoring system consists of 4 elements all obtained 1-year post-transplant: a) eGFR (MDRD), b) DSA, c) urinary protein/creatine ratio, and d) histological abnormalities on a surveillance biopsy.

    Time frame: At 12-months post-transplantation

  2. Incidence of biopsy proven acute rejection (BPAR)

    Time frame: At 12-months post-transplantation

  3. Incidence of proteinuria

    Measured as spot urine protein/creatinine \>1 g/g

    Time frame: At 12-months post-transplantation

  4. Incidence of de novo donor specific anti-Human Leukocyte Antigen (HLA) antibody (DSA)

    Defined as the incidence of de novo DSA on standard of care or protocol directed blood draws up to and including the 12-month protocol blood draw.

    Time frame: At 12-months post-transplantation

  5. Incidence of Grade 3 or higher infections

    Time frame: At 12-months post-transplantation

  6. Incidence of Grade 3 or higher intraoperative or postoperative hemorrhage

    Time frame: Within 4 weeks after transplantation

  7. Incidence of thrombotic or thromboembolic events

    Excluding superficial thrombophlebitis, catheter-related thrombosis and dialysis access thrombosis

    Time frame: Within 4 weeks after transplantation

  8. Incidence of T cell mediated rejection (TCMR) that is steroid resistant

    Time frame: At 12-months post-transplantation

  9. Incidence of TCMR that is BANFF grade 2 or higher

    Time frame: At 12-months post-transplantation

  10. Incidence of antibody mediated rejection (ABMR)

    Time frame: At 12-months post-transplantation

  11. Incidence of death

    Time frame: At 12-months post-transplantation

  12. Incidence of Graft loss (including primary non function)

    Time frame: At 12-months post-transplantation

07

Study locations

4 of 4 sites recruiting
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2025 (actual). Primary completion is estimated for May 2031, 68 months after the start.

Of 17 phase 2 interventional studies under Angioedemas, Hereditary, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 35. This study's planned 68 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 2, 2025
First posted
Apr 9, 2025
StartActual
Sep 22, 2025
Primary completionEst.
May 30, 2031
CompletionEst.
May 30, 2032
Last update
Feb 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06919003
Responsible party
Sponsor
First posted
Apr 9, 2025
Start date
Sep 22, 2025
Primary completion
May 30, 2031 (estimated)
Completion
May 30, 2032 (estimated)
Last update
Feb 27, 2026

Study contacts

Peter S Heeger, MD
study chair · Cedars-Sinai Medical Center
Sindhu Chandran, MBBS, MD
study chair · Cedars-Sinai Medical Center
Stanley Jordan, MD
study chair · Cedars-Sinai Medical Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: C1 esterase inhibitor (human)

Start the discussion